Ionis's RNA Drug TRYNGOLZA Wins FDA Approval for High Triglycerides

CARLSBAD, CA – June 24, 2026 – The landscape of cardiometabolic medicine shifted today as the U.S. Food and Drug Administration (FDA) granted approval to TRYNGOLZA (olezarsen), a novel therapy from Ionis Pharmaceuticals. The drug is the first and only treatment approved to not only lower dangerously high triglycerides but also to significantly reduce the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG). This landmark decision offers a vital new tool for millions of Americans and marks a defining moment for Ionis as it transitions from a niche player in rare diseases to a major commercial force in prevalent conditions.

The Silent Threat of Severe Hypertriglyceridemia

For the estimated three million people in the U.S. living with severe hypertriglyceridemia—a condition defined by triglyceride levels at or above 500 mg/dL—life often involves a constant, low-grade fear. While high cholesterol gets much of the public's attention, extremely high triglycerides carry their own immediate and life-threatening risk: acute pancreatitis. This agonizing condition causes debilitating abdominal pain, often leading to repeated and prolonged hospitalizations, permanent organ damage, and in some cases, death.

Until now, the treatment arsenal has been frustratingly limited. Physicians have relied on a combination of strict dietary changes, exercise, and a handful of medications like fibrates and high-dose omega-3 fatty acids. While these can help, they are often insufficient to bring triglyceride levels below the 500 mg/dL danger threshold. Crucially, no previously approved therapy had ever demonstrated in clinical trials that it could reduce the incidence of acute pancreatitis, leaving a critical unmet need.

“With limited options to lower triglycerides, people living with sHTG often face a constant and real fear that a debilitating acute pancreatitis attack could strike at any time without warning,” said Emily Draud, interim executive director of the National Pancreas Foundation. The approval of TRYNGOLZA, she added, "represents an important new option for this community, offering hope for people who have been waiting for a new treatment."

The RNA Revolution Hits the Mainstream

TRYNGOLZA represents the cutting edge of genetic medicine, a testament to Ionis's three decades of pioneering work in RNA-targeted therapies. It’s not a traditional small molecule pill but a precisely engineered antisense oligonucleotide. Its target is the messenger RNA (mRNA) for a protein called apolipoprotein C-III (apoC-III). Produced in the liver, apoC-III acts like a brake on the body's ability to clear triglycerides from the blood. By intercepting and degrading the apoC-III mRNA, TRYNGOLZA effectively releases this brake, allowing the body to metabolize triglycerides far more efficiently.

The clinical data underpinning the approval, published in the prestigious New England Journal of Medicine, is nothing short of remarkable. The Phase 3 CORE and CORE2 studies showed that the once-monthly, self-administered injection of TRYNGOLZA led to a rapid and sustained reduction in triglyceride levels—by as much as 72% compared to placebo.

More importantly, the therapy delivered on the ultimate clinical goal: preventing pancreatitis. Across the studies, TRYNGOLZA reduced the incidence of acute pancreatitis events by up to 91%. The data was so compelling that the number needed to treat (NNT) to prevent one pancreatitis attack over a year was just four in the highest-risk patients. For context, an NNT below five is considered an exceptional clinical benefit.

“As a physician, I have seen firsthand how challenging it can be for patients with sHTG to lower their triglycerides below 500 mg/dL... which leaves them at risk of a devastating and potentially life-threatening acute pancreatitis attack,” said Dr. Archna Bajaj, an assistant professor of clinical medicine at the University of Pennsylvania. She called TRYNGOLZA a "transformational new therapy" with the potential to "redefine the treatment paradigm.”

A Defining Moment for Ionis Pharmaceuticals

While the approval is a clear victory for patients, it is also a pivotal strategic achievement for Ionis. The Carlsbad-based company has long been a leader in developing drugs for rare, often genetic, diseases, typically partnering with larger pharmaceutical firms for commercialization. TRYNGOLZA’s approval for sHTG marks the company’s first independent launch into a prevalent disease market.

“The approval of TRYNGOLZA marks an historic advance... and a defining moment for Ionis as we bring our groundbreaking medicines to even more patients in need,” said Brett P. Monia, Ph.D., chief executive officer of Ionis. This move signals the company's evolution from a research-and-development powerhouse into a fully integrated, commercial-stage biopharmaceutical company.

Wall Street has taken notice. Ionis's stock has surged over 90% in the past year, largely in anticipation of this approval. The company has boldly projected peak annual revenues for the drug to exceed $3 billion, a figure that reflects the large patient population and the drug's unique clinical profile. This commercial success is expected to fuel Ionis's extensive pipeline, which includes 11 other late-stage medicines targeting neurology and cardiometabolic diseases.

Bringing the Breakthrough to Patients

TRYNGOLZA will be available in the U.S. in July as a 50 mg or 80 mg self-administered autoinjector, taken once a month. Recognizing that access to innovative—and often expensive—medicines can be a hurdle, Ionis has established a comprehensive patient support program called Ionis Every Step™. The program is designed to help patients with insurance verification, prior authorizations, and financial assistance, including programs to potentially lower out-of-pocket costs for commercially insured patients.

The therapy demonstrated a favorable safety profile in its clinical trials, with the most common side effects being injection site reactions and manageable increases in liver enzymes. This profile, combined with its once-monthly convenience and profound efficacy, positions TRYNGOLZA to become the new standard of care for a patient population that has waited decades for a true breakthrough.